PortfoliosLab logo
Amgen Inc. (AMGN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0311621009

CUSIP

031162100

IPO Date

Jun 17, 1983

Highlights

Market Cap

$150.46B

EPS (TTM)

$7.56

PE Ratio

37.02

PEG Ratio

0.94

Total Revenue (TTM)

$25.98B

Gross Profit (TTM)

$16.32B

EBITDA (TTM)

$11.20B

Year Range

$251.27 - $338.98

Target Price

$314.62

Short %

2.62%

Short Ratio

4.59

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Amgen Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20,000.00%40,000.00%60,000.00%80,000.00%100,000.00%120,000.00%140,000.00%NovemberDecember2025FebruaryMarchApril
117,014.26%
3,166.84%
AMGN (Amgen Inc.)
Benchmark (^GSPC)

Returns By Period

Amgen Inc. had a return of 8.62% year-to-date (YTD) and 7.43% in the last 12 months. Over the past 10 years, Amgen Inc. had an annualized return of 8.73%, while the S&P 500 had an annualized return of 10.11%, indicating that Amgen Inc. did not perform as well as the benchmark.


AMGN

YTD

8.62%

1M

-8.14%

6M

-9.97%

1Y

7.43%

5Y*

6.76%

10Y*

8.73%

^GSPC (Benchmark)

YTD

-6.06%

1M

-3.27%

6M

-4.87%

1Y

9.44%

5Y*

14.30%

10Y*

10.11%

*Annualized

Monthly Returns

The table below presents the monthly returns of AMGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20259.51%8.80%1.13%-9.86%8.62%
20249.11%-12.18%3.83%-3.65%12.44%2.16%6.41%1.11%-3.48%-0.64%-10.94%-7.86%-6.77%
2023-3.90%-7.41%4.36%-0.83%-7.09%0.62%5.46%10.36%4.85%-4.86%6.28%6.82%13.46%
20220.96%0.56%6.77%-3.57%10.98%-5.23%1.71%-2.15%-6.20%19.94%6.67%-8.30%20.43%
20215.01%-6.14%10.62%-3.69%-0.01%2.44%-0.91%-5.91%-5.71%-2.67%-3.10%13.12%0.89%
2020-10.38%-6.90%1.50%18.00%-3.33%2.68%3.74%4.23%0.33%-14.64%3.05%3.55%-1.99%
2019-3.88%2.37%-0.05%-5.61%-6.24%10.55%1.25%12.60%-7.24%10.20%10.80%2.71%27.60%
20186.99%-0.48%-7.23%2.35%3.74%2.77%6.48%2.35%3.74%-7.00%8.77%-6.52%15.23%
20177.16%13.45%-7.06%-0.46%-4.26%10.94%1.32%2.56%4.88%-6.02%0.94%-1.00%22.27%
2016-5.91%-6.19%5.38%5.58%0.44%-3.67%13.07%-0.57%-1.91%-15.38%2.74%1.49%-7.57%
2015-4.41%4.13%1.35%-1.21%-0.56%-1.75%15.03%-13.65%-8.87%14.36%2.36%0.76%3.95%
20144.27%4.79%-0.55%-9.40%4.36%2.05%7.62%9.94%0.77%15.46%2.32%-3.64%42.33%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AMGN is 57, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AMGN is 5757
Overall Rank
The Sharpe Ratio Rank of AMGN is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of AMGN is 5252
Sortino Ratio Rank
The Omega Ratio Rank of AMGN is 5252
Omega Ratio Rank
The Calmar Ratio Rank of AMGN is 6464
Calmar Ratio Rank
The Martin Ratio Rank of AMGN is 5959
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Amgen Inc. (AMGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for AMGN, currently valued at 0.21, compared to the broader market-2.00-1.000.001.002.003.00
AMGN: 0.21
^GSPC: 0.46
The chart of Sortino ratio for AMGN, currently valued at 0.50, compared to the broader market-6.00-4.00-2.000.002.004.00
AMGN: 0.50
^GSPC: 0.77
The chart of Omega ratio for AMGN, currently valued at 1.07, compared to the broader market0.501.001.502.00
AMGN: 1.07
^GSPC: 1.11
The chart of Calmar ratio for AMGN, currently valued at 0.26, compared to the broader market0.001.002.003.004.005.00
AMGN: 0.26
^GSPC: 0.47
The chart of Martin ratio for AMGN, currently valued at 0.57, compared to the broader market-5.000.005.0010.0015.0020.00
AMGN: 0.57
^GSPC: 1.94

The current Amgen Inc. Sharpe ratio is 0.21. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Amgen Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.21
0.46
AMGN (Amgen Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Amgen Inc. provided a 3.25% dividend yield over the last twelve months, with an annual payout of $9.13 per share. The company has been increasing its dividends for 13 consecutive years.


1.50%2.00%2.50%3.00%3.50%$0.00$2.00$4.00$6.00$8.0020142015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020201920182017201620152014
Dividend$9.13$9.00$8.52$7.76$7.04$6.40$5.80$5.28$4.60$4.00$3.16$2.44

Dividend yield

3.25%3.45%2.96%2.95%3.13%2.78%2.41%2.71%2.65%2.74%1.95%1.53%

Monthly Dividends

The table displays the monthly dividend distributions for Amgen Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025$0.00$2.38$0.00$0.00$2.38
2024$0.00$2.25$0.00$0.00$2.25$0.00$0.00$2.25$0.00$0.00$2.25$0.00$9.00
2023$0.00$2.13$0.00$0.00$2.13$0.00$0.00$2.13$0.00$0.00$2.13$0.00$8.52
2022$0.00$1.94$0.00$0.00$1.94$0.00$0.00$1.94$0.00$0.00$1.94$0.00$7.76
2021$0.00$1.76$0.00$0.00$1.76$0.00$0.00$1.76$0.00$0.00$1.76$0.00$7.04
2020$0.00$1.60$0.00$0.00$1.60$0.00$0.00$1.60$0.00$0.00$1.60$0.00$6.40
2019$0.00$1.45$0.00$0.00$1.45$0.00$0.00$1.45$0.00$0.00$1.45$0.00$5.80
2018$0.00$1.32$0.00$0.00$1.32$0.00$0.00$1.32$0.00$0.00$1.32$0.00$5.28
2017$0.00$1.15$0.00$0.00$1.15$0.00$0.00$1.15$0.00$0.00$1.15$0.00$4.60
2016$0.00$1.00$0.00$0.00$1.00$0.00$0.00$1.00$0.00$0.00$1.00$0.00$4.00
2015$0.00$0.79$0.00$0.00$0.79$0.00$0.00$0.79$0.00$0.00$0.79$0.00$3.16
2014$0.61$0.00$0.00$0.61$0.00$0.00$0.61$0.00$0.00$0.61$0.00$2.44

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%25.0%
AMGN: 3.3%
Amgen Inc. has a dividend yield of 3.25%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%1,000.0%1,200.0%
AMGN: 46.7%
Amgen Inc. has a payout ratio of 46.72%, which is quite average when compared to the overall market. This suggests that Amgen Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-15.41%
-10.07%
AMGN (Amgen Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Amgen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amgen Inc. was 78.02%, occurring on Nov 19, 1984. Recovery took 336 trading sessions.

The current Amgen Inc. drawdown is 15.41%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-78.02%Jun 20, 1983361Nov 19, 1984336Mar 21, 1986697
-63.5%Mar 18, 1987155Oct 26, 1987405Jun 2, 1989560
-60.17%Jul 24, 2000494Jul 15, 2002760Jul 20, 20051254
-59.49%Dec 2, 1992176Aug 12, 1993470Jun 22, 1995646
-53.61%Sep 20, 2005628Mar 19, 20081119Aug 24, 20121747

Volatility

Volatility Chart

The current Amgen Inc. volatility is 10.61%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2025FebruaryMarchApril
10.61%
14.23%
AMGN (Amgen Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Amgen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Amgen Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
AMGN: 37.0
The chart displays the Price-to-Earnings (P/E) ratio for AMGN, comparing it with other companies in the Drug Manufacturers - General industry. Currently, AMGN has a P/E ratio of 37.0. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
2.04.06.08.010.0
AMGN: 0.9
The chart shows the Price/Earnings to Growth (PEG) ratio for AMGN compared to other companies in the Drug Manufacturers - General industry. AMGN currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
2.04.06.08.010.0
AMGN: 4.5
This chart shows the Price-to-Sales (P/S) ratio for AMGN relative to other companies in the Drug Manufacturers - General industry. Currently, AMGN has a P/S ratio of 4.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
2.04.06.08.010.0
AMGN: 25.4
The chart illustrates the Price-to-Book (P/B) ratio for AMGN in comparison with other companies in the Drug Manufacturers - General industry. Currently, AMGN has a P/B value of 25.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items